NanoVibronix NAOV shares are trading higher on Wednesday.
The company announced it has received reimbursement approval from the U.S. Centers for Medicare & Medicaid Services for its PainShield.
NanoVibronix focuses on the manufacturing and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
NanoVibronix shares were trading up 40.10% to $2.90 in Wednesday’s pre-market session. The stock has a 52-week high of $4.50 and a 52-week low of $1.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
